Compare Manhattan Associates Inc (MANH) vs Organon & Co. Common Stock (OGN) Price & Performance

MANH trades at $222.71, up 2.21% today, near its pivot point of $222. The stock shows strong technical momentum with a bullish moving average signal. Fundamentally, the company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.39 exceeding the $1.32 estimate. High profitability is evident with a net margin of 18.67% and ROE of 96.38%, though valuation multiples like a P/E of 63.07 are elevated. Recent news includes a product launch of 'Editions' for scalable solutions but also ongoing legal investigations into fiduciary duties.

The outlook is mixed; strong earnings momentum and analyst consensus (80% buy ratings) support upside toward the $260 high target, but high valuation and legal overhang pose risks. The stock's current level near resistance at $226 requires monitoring for a breakout or pullback. Key catalysts include Q3 2026 earnings and resolution of the legal scrutiny.

Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.

OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.